Related Experiment Video
Updated: May 11, 2026

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
Published on: July 4, 2007
Calcineurin inhibitor encephalopathy
1Neuro-Oncology/Department of Neurology, University of Michigan, Ann Arbor, MI 48109-5316, USA. amammose@med.umich.edu
Abstract:
Calcineurin inhibitor encephalopathy (CIE) is a rare condition occurring in patients who are undergoing treatment with drugs from the calcineurin inhibitor (CI) family of immunosuppressants, either cyclosporine (CsA) or tacrolimus (TAC, FK506). Generally acute in onset, the symptoms are commonly reversible if properly managed in a timely fashion. The differential diagnosis is broad and an evaluation should include toxic, metabolic, infectious and ischemic causes, with abnormal cerebrospinal fluid (CSF) results (aside from elevated protein concentration in isolation), suggesting an etiology other than CIE. Neurologic deficits are generally reversible; however, the risk of permanent deficits or poor outcomes increases the longer the condition goes unrecognized.
Related Concept Videos
Encephalitis l: Introduction
Hepatic Encephalopathy
Encephalitis ll: Pathophysiology
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cerebral Edema ll: Pathophysiology

